SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into clinical trial interpretation and treatment efficacy (and incorrect graphs).Takeaways Clinical Trial DataTreatment Efficacy Chapters 00:00 Introduction to IGNYTE Study14:04 Response Rate and Safety Profile25:17 RNA-seq Analysis and Toxicity
No transcript for this episode yet
You can still listen to it in the player. On episodes with a transcript, you can tap any word to see its meaning.
